NASDAQ / LIVE COMPANY INTELLIGENCE

uniQure N.V.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERQURE
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / QURE COVERAGE

What’s moving uniQure N.V. now

Current reporting with the operating signal separated from the noise.

01
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock?

Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock?

Investors are testing whether uniQure N.V.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

Investors are testing whether uniQure N.V.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

The development tests whether uniQure N.V. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
04
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

Investors are testing whether uniQure N.V.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
uniQure N.V. Receives Positive Recommendation to Proceed with Second Dose Cohort in AMT-162 Clinical Trial for SOD1-ALS

uniQure N.V. Receives Positive Recommendation to Proceed with Second Dose Cohort in AMT-162 Clinical Trial for SOD1-ALS

The story matters when it changes uniQure N.V.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest QURE filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-29 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-05 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-02 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-29 · Period 2026-07-29SEC ↗8-KMaterial company eventFiled 2026-06-24 · Period 2026-06-23SEC ↗8-KMaterial company eventFiled 2026-06-22 · Period 2026-06-19SEC ↗6-KOfficial SEC filingFiled 2016-12-19 · Period 2016-12-19SEC ↗6-KOfficial SEC filingFiled 2016-12-15 · Period 2016-12-15SEC ↗
EARNINGS / QUARTERLY TRACKER

uniQure N.V., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.